Aegis Capital Starts BiondVax Pharmaceuticals (BVXV) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts BVXV Hot Sheet
Price: $1.36 --0%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Aegis Capital earlier initiated coverage on BiondVax Pharmaceuticals (NASDAQ: BVXV) with a Buy rating and a price target of $15.00.
For an analyst ratings summary and ratings history on BiondVax Pharmaceuticals click here. For more ratings news on BiondVax Pharmaceuticals click here.
Shares of BiondVax Pharmaceuticals closed at $4.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Erste Group Starts Nasdaq OMX Group Inc. (NDAQ) at Buy
- Maxim Group Starts Nasus Pharma Ltd (NSRX) at Buy
- UBS Starts DO & CO AG (DOC:AV) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
